AIM Vaccine Co Ltd
06660
Company Profile
Business description
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain, ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates the majority of its revenues in the PRC.
Contact
2 Ronghua South Road
26th Floor, Building T6, Han’s Plaza
Economic Technological Development Area
Beijing
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,535
Stocks News & Analysis
stocks
ASX reporting season wrap: BHP, banks, CSL bloodbath and more
A round up of notable stories and reactions as ASX earnings season continues.
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,234.30 | 55.70 | -0.60% |
| CAC 40 | 7,969.69 | 31.40 | 0.40% |
| DAX 40 | 24,363.09 | 69.75 | 0.29% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,339.14 | 234.53 | 0.93% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,633.29 | 23.12 | 0.05% |
| NZX 50 Index | 13,042.76 | 151.31 | -1.15% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 8,967.40 | 57.00 | -0.63% |
| SSE Composite Index | 3,825.76 | 54.66 | 1.45% |